Background Large clinical trials established the benefits of sodium-glucose cotransporter 2
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …

Background: Empagliflozin improves outcomes in patients with heart failure with a preserved
ejection fraction, but whether the effects are consistent in patients with and without diabetes …

Importance Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes in
patients with heart failure and a reduced ejection fraction (HFrEF). The association with …

Background Inhibition of the sodium-glucose cotransporter-2 (SGLT2i) improves outcomes
in patients with heart failure (HF) and reduced ejection fraction (HFrEF), but the mechanism …

Background Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, but their effects in …

Aims To investigate the effect of the sodium-glucose co-transporter-2 inhibitor empagliflozin
on N-terminal pro-b-type natriuretic peptide (NT-proBNP) in patients with heart failure (HF) …

Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure
hospitalization and cardiovascular death in patients with heart failure and reduced ejection …

Aims No therapy has shown to reduce the risk of hospitalization for heart failure across the
entire range of ejection fractions seen in clinical practice. We assessed the influence of …

Abstract Aims The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms
In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise …

Importance The diuretic effect of sodium-glucose cotransporter 2 inhibitors may result in
interaction with background diuretic therapy in patients with heart failure and preserved …